TRSB.F logo

3SBio OTCPK:TRSB.F Stock Report

Last Price

US$0.80

Market Cap

US$1.7b

7D

0%

1Y

n/a

Updated

26 Sep, 2022

Data

Company Financials +

TRSB.F Stock Overview

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

TRSB.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends3/6

3SBio Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share PriceHK$0.80
52 Week HighHK$0.80
52 Week LowHK$0.80
Beta0.76
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-66.94%

Recent News & Updates

Recent updates

Shareholder Returns

TRSB.FUS BiotechsUS Market
7D0%0.9%0.4%
1Yn/a10.3%28.8%

Return vs Industry: Insufficient data to determine how TRSB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how TRSB.F performed against the US Market.

Price Volatility

Is TRSB.F's price volatile compared to industry and market?
TRSB.F volatility
TRSB.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TRSB.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TRSB.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,160Jing Louhttps://www.3sbio.com

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
TRSB.F fundamental statistics
Market capUS$1.71b
Earnings (TTM)US$239.03m
Revenue (TTM)US$891.54m

7.2x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRSB.F income statement (TTM)
RevenueCN¥6.37b
Cost of RevenueCN¥1.11b
Gross ProfitCN¥5.25b
Other ExpensesCN¥3.55b
EarningsCN¥1.71b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin82.52%
Net Profit Margin26.81%
Debt/Equity Ratio26.4%

How did TRSB.F perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

24%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.